TEV-50717

Phase 3Small molecule

Teva

TEV-50717 is one of 63 small molecule programs targeting Cerebral Palsy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

Tourette SyndromeActive, not recruiting

Cerebral PalsyPhase 3

Active, not recruiting

Tourette SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Cerebral Palsy

#DrugCompanyPhaseTrials

Ingrezza

Neurocrine Biosciences

Phase 3

1 2

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

3 3

Cyklokapron

AAmring

Phase 3

1 4

Advil

KKenvue Brands

Phase 3

1 5

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 6

Dysport

Ipsen

Phase 3

1 7

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Phase 3

1 8

Fosamax

Mylan Pharmaceuticals Inc

Phase 3

1 9

PROCRIT

WWim Janssens

Phase 2

3 10

Osmitrol

BB. Braun Medical Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tourette syndrome3 trials

Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Completed· Teva logo

Teva·Phase 2/3·NCT03452943·119 enrolled

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Terminated· Teva logo

Teva·Phase 3·NCT03567291·228 enrolled

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

Completed· Teva logo

Teva·Phase 3·NCT03571256·158 enrolled

Cerebral Palsy2 trials

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Terminated· Teva logo

Teva·Phase 3·NCT04200352·44 enrolled

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

Completed· Teva logo

Teva·Phase 3·NCT03813238·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TEV-50717. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TEV-50717 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TEV-50717. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Teva

TEV-50717

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tourette syndrome3 trials

Cerebral Palsy2 trials

References

Drug Info

Quick Facts

Related News